| Literature DB >> 19844579 |
Ji-Hyun Lee1, Michael J Schell, Richard Roetzheim.
Abstract
The group randomized trial (GRT) is a common study design to assess the effect of an intervention program aimed at health promotion or disease prevention. In GRTs, groups rather than individuals are randomized into intervention or control arms. Then, responses are measured on individuals within those groups. A number of analytical problems beset GRT designs. The major problem emerges from the likely positive intraclass correlation among observations of individuals within a group. This paper provides an overview of the analytical method for GRT data and applies this method to a randomized cancer prevention trial, where multiple binary primary endpoints were obtained. We develop an index of extra variability to investigate group-specific effects on response. The purpose of the index is to understand the influence of individual groups on evaluating the intervention effect, especially, when a GRT study involves a small number of groups. The multiple endpoints from the GRT design are analyzed using a generalized linear mixed model and the stepdown Bonferroni method of Holm.Entities:
Mesh:
Year: 2009 PMID: 19844579 PMCID: PMC2760209 DOI: 10.1371/journal.pone.0007265
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics at individual level by arm (4 groups per arm).
| Control Arm | Intervention Arm | ||||
| Characteristics | n = 467 | % | n = 468 | % | p-value |
|
| 0.270 | ||||
| Under 50 | 5 | 1.1 | 7 | 1.5 | |
| 50–59 | 235 | 50.3 | 258 | 55.1 | |
| 60 | 227 | 48.6 | 203 | 43.4 | |
|
| 0.014 | ||||
| White | 222 | 47.5 | 200 | 44.0 | |
| Black | 114 | 24.4 | 157 | 33.6 | |
| Hispanic | 120 | 25.7 | 98 | 20.9 | |
| Other | 11 | 3.2 | 7 | 1.5 | |
|
| 0.005 | ||||
| Married | 106 | 22.7 | 145 | 31.0 | |
| Non-married | 361 | 77.3 | 323 | 69.0 | |
|
| 0.263 | ||||
| English | 361 | 77.3 | 376 | 80.3 | |
| Non-English | 106 | 22.7 | 92 | 19.7 | |
|
| 0.506 | ||||
| County Health Plan | 287 | 61.5 | 277 | 59.2 | |
| Medicaid | 65 | 13.9 | 79 | 16.9 | |
| Medicare | 88 | 18.8 | 80 | 17.1 | |
| Other | 27 | 5.8 | 32 | 6.8 | |
|
| 0.706 | ||||
| Smoker | 114 | 24.4 | 120 | 25.6 | |
| Non-smoker | 353 | 75.6 | 348 | 74.4 | |
|
| |||||
|
| 0.049 | ||||
| Yes | 268 | 57.6 | 239 | 51.1 | |
| No | 197 | 42.3 | 229 | 48.9 | |
Distribution of screening ( subjects who took screening test/total subjects) by clinic nested within arm and time combination in the cancer SOS study.
| Control Arm | Intervention Arm | |||||||
| Test | Clinic | Baseline | 12 mths | 24 mths | Clinic | Baseline | 12 mths | 24 mths |
|
| ||||||||
| 2 | 31/54 | 43/68 | 40/85 | 5 | 48/69 | 50/70 | 56/79 | |
| 7 | 43/65 | 23/54 | 25/66 | 6 | 35/51 | 51/70 | 43/68 | |
| 8 | 27/65 | 22/78 | 28/72 | 9 | 37/70 | 35/79 | 12/78 | |
| 10 | 47/73 | 46/77 | 46/83 | 11 | 31/54 | 40/63 | 28/69 | |
| Total | 148/257 | 134/277 | 139/306 | 151/244 | 176/282 | 139/294 | ||
| Rate (%) | 57.6 | 48.4 | 45.4 | 61.9 | 62.4 | 47.3 | ||
| Difference | ||||||||
| from Control Arm (%) | 4.3 | 14.0 | 1.9 | |||||
|
| ||||||||
| 2 | 64/89 | 87/107 | 80/116 | 5 | 95/114 | 108/127 | 82/113 | |
| 7 | 105/124 | 85/116 | 79/111 | 6 | 88/116 | 79/115 | 91/122 | |
| 8 | 67/115 | 55/111 | 59/118 | 9 | 57/107 | 82/119 | 54/119 | |
| 10 | 101/116 | 95/120 | 83/117 | 11 | 85/118 | 95/119 | 92/120 | |
| Total | 337/444 | 322/454 | 301/462 | 325/455 | 364/480 | 319/474 | ||
| Rate (%) | 75.9 | 70.9 | 65.1 | 71.4 | 75.8 | 67.3 | ||
| Difference | ||||||||
| from Control Arm (%) | −4.5 | 4.9 | 2.2 | |||||
|
| ||||||||
| 2 | 2/98 | 11/120 | 5/118 | 5 | 52/118 | 54/127 | 44/119 | |
| 7 | 36/126 | 15/119 | 19/112 | 6 | 6/119 | 67/119 | 41/126 | |
| 8 | 42/117 | 4/116 | 9/122 | 9 | 40/108 | 4/118 | 17/122 | |
| 10 | 30/121 | 29/125 | 26/117 | 11 | 67/118 | 68/122 | 37/122 | |
| Total | 110/462 | 59/480 | 59/469 | 165/463 | 193/486 | 139/489 | ||
| Rate (%) | 23.8 | 12.3 | 12.6 | 35.6 | 39.7 | 28.4 | ||
| Difference | ||||||||
| from Control Arm (%) | 11.8 | 27.4 | 15.8 | |||||
Time unit is in months (mths).
Figure 1Screening rate in percentage by each clinic (four clinics per arm) for each test across years (: intervention clinics and : control clinics).
The bold lines within each graph represent the average screening rate for each arm respectively.
Summary results of the univariate GLMM analyses for the cancer SOS study.
| Test | Estimate | Standard Error | Adjusted | ||
| Fixed Effect |
| S.E. | DF | p-value | p-value |
|
| |||||
| Intercept | 2.937 | 0.569 | 303.3 | 0.0 | |
| Intervention | 0.385 | 0.308 | 6.7 | 0.25 | |
| Time | −0.022 | 0.014 | 6.1 | 0.17 | |
| Intervention | −0.006 | 0.020 | 6.4 | 0.78 | 1.0 |
| Age | −0.041 | 0.009 | 1654 | 0.0 | |
| Race:Hispanic | 0.288 | 0.114 | 1654 | 0.012 | |
|
| |||||
| Intercept | 1.201 | 0.532 | 6.9 | 0.092 | |
| Intervention | −0.144 | 0.425 | 6.9 | 0.71 | |
| Time | −0.279 | 0.082 | 6.2 | 0.015 | |
| Intervention | 0.180 | 0.115 | 6.0 | 0.17 | 0.51 |
|
| |||||
| Intercept | −2.282 | 0.632 | 30.5 | 0.011 | |
| Intervention | 0.914 | 0.583 | 5.6 | 0.17 | |
| Time | −0.441 | 0.299 | 6.3 | 0.19 | |
| Intervention | 0.221 | 0.416 | 5.9 | 0.61 | 1.0 |
| Age | −0.041 | 0.009 | 1654 | 0.0 |
Estimates of covariance-parameters and intra-class coefficient (ICC) & variance inflation factor (VIF) from the univariate GLMMs.
| Test |
|
|
|
|
|
| Pap Smear | 0.139 | 0.085 | 1.00 | 0.069 | 5.7 |
| Mammography | 0.321 | 0.004 | 1.00 | 0.003 | 1.3 |
| FOBT | 0.632 | 0.312 | 1.01 | 0.160 | 19.9 |
Figure 2Percent change (%) between two time points by each clinic and arm for each screening test, with index of extra variability (IEV): Arm I0-1,I1-2, C0-1, C1-2: Intervention (I) and Control (C) between baseline and year 1 (0–1) and between year 1 and 2 (1–2).
: Mean of difference between two time points across clinics. : Individual clinics' difference in screening proportion between two time points. : 90 CI based on binomial distribution.